Medivation NDA ACCEPTED and 4 Stocks Enjoying 52-Week Highs

Cynosure, Inc. (NASDAQ:CYNO) reports a second quarter earnings per share of 20 cents, against a consensus of 10 cents. Shares closed up 1087 percent on the day at $23.86, and have been traded in a 52-week range of $8.84 to $23.00.

D.R. Horton, Inc. (NYSE:DHI): Home prices in the second quarter were up year-over-year for the first time since 2007. The prices rose 0.2 percent, according to the real estate firm Zillow’s closely watched index, which represents the latest sign that the housing market is beginning to recover, reports the Wall Street Journal. Shares closed down 2.1 percent on the day at $18.67, having traded in a 52-week range of $8.03 to $19.34.

Investing Insights: Wall St. Brief: Apple PLUNGES After Earnings Miss, Netflix FALLS 17%.

Jarden Corp. (NYSE:JAH) posted a second quarter adjusted earnings per share of $1.14, compared to consensus of $1.10. Shares closed up 0.35 percent on the day at $43.59, and have traded in a 52-week range of $25.60 to $44.52.

M.D.C. Holdings (NYSE:MDC) shares closed down 2.38 percent on the day at $32.39, have been traded in a 52-week range of $14.79 to $33.43.

Medivation, Inc. (NASDAQ:MDVN) and Astellas Pharma reported that the FDA has accepted for filing the New Drug Application for enzalutamide, formerly known as MDV3100, for the potential treatment of men suffering from castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy and granted Priority Review Designation. The FDA’s acceptance of the Application triggers a $10 million milestone payment to Medivation, through its Collaboration Agreement with Astellas. Shares closed up 2.96 percent on the day at $96.03, and have traded in a 52-week range of $14.32 to $96.80.

Don’t Miss: Ford Earnings: Profit Falls, Yet Revenue TOPS Analyst Estimate.

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.